292 related articles for article (PubMed ID: 30317696)
1. New Systemic Treatments in Advanced Hepatocellular Carcinoma.
Sanduzzi-Zamparelli M; Díaz-Gonzalez Á; Reig M
Liver Transpl; 2019 Feb; 25(2):311-322. PubMed ID: 30317696
[TBL] [Abstract][Full Text] [Related]
2. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Bangaru S; Marrero JA; Singal AG
Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
[TBL] [Abstract][Full Text] [Related]
3. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
Su GL; Altayar O; O'Shea R; Shah R; Estfan B; Wenzell C; Sultan S; Falck-Ytter Y
Gastroenterology; 2022 Mar; 162(3):920-934. PubMed ID: 35210014
[TBL] [Abstract][Full Text] [Related]
4. Molecular therapies for HCC: Looking outside the box.
Faivre S; Rimassa L; Finn RS
J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
[TBL] [Abstract][Full Text] [Related]
5. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
Zhang CH; Li M; Lin YP; Gao Q
Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
[TBL] [Abstract][Full Text] [Related]
6. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment for hepatocellular carcinoma.
Ján T; Dáša S; Igor A; Jana V
Klin Onkol; 2020; 33(5):356-361. PubMed ID: 33108880
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
[TBL] [Abstract][Full Text] [Related]
9. Review article: systemic treatment of hepatocellular carcinoma.
Pinter M; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
[TBL] [Abstract][Full Text] [Related]
10. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Chen J; Wang J; Xie F
Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
13. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.
Yarchoan M; Agarwal P; Villanueva A; Rao S; Dawson LA; Llovet JM; Finn RS; Groopman JD; El-Serag HB; Monga SP; Wang XW; Karin M; Schwartz RE; Tanabe KK; Roberts LR; Gunaratne PH; Tsung A; Brown KA; Lawrence TS; Salem R; Singal AG; Kim AK; Rabiee A; Resar L; Hoshida Y; He AR; Ghoshal K; Ryan PB; Jaffee EM; Guha C; Mishra L; Coleman CN; Ahmed MM
Cancer Res; 2019 Sep; 79(17):4326-4330. PubMed ID: 31481419
[TBL] [Abstract][Full Text] [Related]
14. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
Altayar O; Shah R; Chang CY; Falck-Ytter Y; Muir AJ
Gastroenterology; 2022 Mar; 162(3):937-951. PubMed ID: 35210015
[No Abstract] [Full Text] [Related]
15. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
Tovoli F; Lorenzo S; Barbera MA; Garajova I; Frega G; Palloni A; Pantaleo MA; Biasco G; Brandi G
Future Oncol; 2017 Sep; 13(21):1893-1905. PubMed ID: 28693355
[TBL] [Abstract][Full Text] [Related]
16. An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.
Ielasi L; Sansone V; Granito A; Benevento F; De Lorenzo S; Tovoli F
Drugs Today (Barc); 2018 Oct; 54(10):615-627. PubMed ID: 30398482
[TBL] [Abstract][Full Text] [Related]
17. Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes.
Mahn R; Sadeghlar F; Bartels A; Zhou T; Weismüller T; Kupczyk P; Meyer C; Gaertner FC; Toma M; Vilz T; Knipper P; Glowka T; Manekeller S; Kalff J; Strassburg CP; Gonzalez-Carmona MA
Medicine (Baltimore); 2021 Sep; 100(38):e27082. PubMed ID: 34559100
[TBL] [Abstract][Full Text] [Related]
18. Molecular therapies and precision medicine for hepatocellular carcinoma.
Llovet JM; Montal R; Sia D; Finn RS
Nat Rev Clin Oncol; 2018 Oct; 15(10):599-616. PubMed ID: 30061739
[TBL] [Abstract][Full Text] [Related]
19. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM
Gastroenterology; 2021 Sep; 161(3):879-898. PubMed ID: 34126063
[TBL] [Abstract][Full Text] [Related]
20. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
de'Angelis N; Landi F; Carra MC; Azoulay D
World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]